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Background. There is no exact consensus about the usefulness of the Mycobacterium tuberculosis polymerase
chain reaction (PCR) testing for the diagnosis of tuberculous pleural effusion because of the diverse PCR methods
and the different diagnostic criteria that are described in other studies.
Methods. We analyzed pleural effusion specimens obtained from 111 patients for whom the exclusion of the
possibility of tuberculous pleural effusion was necessary. We performed M. tuberculosis PCR testing using the
Cobas Amplicor MTB test (Roche Diagnostic Systems), which is fully automated and commercially available.
Results. Results of the M. tuberculosis PCR test of pleural effusion specimens were positive for 7 (17.1%) of
the 41 patients with confirmed pleural tuberculosis and for 3 (18.8%) of the 16 patients with probable pleural
tuberculosis. The overall sensitivity and specificity of M. tuberculosis PCR testing of pleural effusion were 17.5%
and 98.1%, respectively. The sensitivity of M. tuberculosis PCR testing for each group of patients with tuberculous
pleural effusion detected by smear-positive results, smear-negative and culture-positive results, and culture-negative
and pleural biopsy–positive results, was 100.0%, 33.3%, and 3.7%, respectively. Of the 57 patients with pleural
tuberculosis, only 3 (5.3%) had positive results of M. tuberculosis PCR testing along with negative results of
smearing, negative results of pleural pathological analysis, and a low level of adenosine deaminase.
Conclusion. For specimens such as pleural effusion, in which the bacillary load is very low, the clinical utility
of PCR testing seems highly limited.
Tuberculosis is still a major health problem worldwide.
It is estimated that 8–9 million new cases develop every
year, of which 3–4 million cases have smear-positive
results [1]. The recent increase in tuberculosis in the
world and the emergence of multidrug-resistant strains
have prompted more rapid and sensitive methods in
the laboratory diagnosis than previous conventional di-
agnostic techniques. The diagnosis of tuberculosis at
an earlier stage would be advantageous, because it is
less contagious and is associated with a lower morbidity
and mortality during the early stage [2–4]. Although
culture of Mycobacterium tuberculosis continues to be
the gold standard in the diagnosis of tuberculosis, the
results are neither satisfactorily sensitive nor rapid. My-
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cobacterial culture takes at least 2 weeks to perform,
depending on the culture media that is used [5]. Nucleic
acid amplification tests (NATs), including PCR, have
improved the accuracy of and the time for diagnosis
of tuberculosis made on the basis of examination of
respiratory specimens. For nonrespiratory specimens,
such as pleural effusion specimens, however, previous
studies have shown highly variable results regarding the
usefulness of NATs because of the use of different in-
house NAT methods, small study populations, and di-
verse criteria for pleural tuberculosis.
The Cobas Amplicor MTB test (Roche Diagnostic
Systems) is a well established and commercially avail-
able PCR test commonly used for the direct detection
of M. tuberculosis in clinical samples. The test uses bio-
tinylated genus-specific primers (KY18 and KY75) to
amplify the 584–base-pair sequence within the 1500–
base-pair region encoding 16s rRNA of MTB. The test
combines 5 instruments into 1 (a thermal cycler, an
automatic pipettor, an incubator, a washer, and a
reader). Because it is fully automated for amplification
and detection and is consolidated into a single instru-
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ment, it is thought to be able to minimize interindividual var-
iabilities. Furthermore, because it binds M. tuberculosis–specific
oligonucleotide probes to the amplified sequences, it can in-
crease the overall specificity.
Tuberculous pleural effusion occurs in up to 30% of patients
with tuberculosis [6] and accounts for the major portion of
the morbidity associated with extrapulmonary tuberculosis [7].
However, the number of organisms in pleural effusion speci-
mens obtained from most patients with tuberculous pleuritis
is relatively low, with positive culture results in !25% of cases.
Even pleural biopsy reveals granulomatous inflammation only
in ∼60% of patients [8]. PCR has been used to detect M.
tuberculosis in pleural fluid samples, with highly variable sen-
sitivities (11%–81%) in previous studies with different in-house
PCR methods [9–14]. This is why we investigated the clinical
utility of M. tuberculosis PCR testing with the Cobas Amplicor
MTB Analyzer with regard to the rapid and accurate diagnosis
of pleural tuberculosis.
METHODS
Study population and samples. One hundred eleven patients
118 years of age, for whom the exclusion of the possibility of
tuberculous pleural effusion was necessary, were prospectively
analyzed over a 2-year period (August 2002–August 2004) at
the Yonsei University Medical Center (Seoul, Korea). Suspicion
of pleural tuberculosis was based on unilateral pleural effusion
with clinical manifestations suggestive of tuberculosis, such as
productive cough, chronic low-grade fever, weight loss, ano-
rexia, and night sweating. Pleural effusion specimens obtained
from all 111 patients were subjected to routine analysis, acid-
fast bacilli (AFB) smear, mycobacterial culture, M. tuberculosis
PCR with the Cobas Amplicor MTB Analyzer, measurement of
the adenosine deaminase (ADA) level, Gram staining, bacterial
culture, and cytologic examination. Sputum samples were col-
lected in the morning from each patient and were used for
AFB smear and mycobacterial culture. Pleural biopsy and path-
ologic examination were not performed for 32 of the 111 pa-
tients because of the small amount of pleural effusion. Informed
consent was obtained from each patient. The use of the samples
and the study protocols were reviewed and approved by our
institutional review board.
Diagnostic criteria of pleural tuberculosis. A case of con-
firmed pleural tuberculosis was defined as having one of the
following characteristics: a pleural fluid sample that was cul-
ture-positive for M. tuberculosis and/or a histopathologic find-
ing consistent with tuberculosis on pleural biopsy. A case of
probable pleural tuberculosis was defined as having one of the
following characteristics: a sputum specimen that was culture-
positive for M. tuberculosis and/or other biologic specimens that
were culture-positive for M. tuberculosis and/or a positive re-
sponse to antituberculosis medication without other possible
causes of pleural effusion.
AFB smear and mycobacterial culture. For microscopic
examination, Ziehl-Neelsen staining was performed. After each
of the collected sputum and pleural effusion samples was de-
contaminated by an equal volume of 4% sodium hydroxide
(NaOH) solution, 2 slopes of Ogawa media containing 3%
potassium dihydrogen phosphate (KH2PO4) (3% Ogawa me-
dia) were inoculated with them [15]. The inoculated medium
was incubated at 35C–37C until the growth was observed or
was discarded as negative after 8 weeks.
Determination of ADA activity in pleural effusion. ADA
activity was determined with 2 mL of pleural fluid, according
to the colorimetric method described by Giusti and Galanti
[16]. An ADA level of !45 IU/L was considered to be a negative
finding.
Tuberculin skin test. Tuberculin skin testing was not per-
formed in this study because there were difficulties in inter-
preting the results in Korea, where a Mycobacterium bovis ba-
cillus Calmette-Guerin (BCG) vaccination program covers
190% of the population.
Nucleic acid amplification and detection techniques.
Specimen preparation was as follows: 10 mL of each pleural
fluid specimen was decontaminated with an equal amount of
4% NaOH solution and was centrifuged at 3000 g for 20 min
to collect the sediment. One hundred mL of sediment from each
pleural effusion sample was transferred to a microcentrifuge
tube containing 500 mL of washing solution and centrifuged at
12,500 g for 10 min. The supernatant was discarded, and 100
mL of specimen lysis reagent was added to extract a DNA tem-
plate. The mixture was vortexed and incubated at 60C in a
dry-heat block for 45 min, after which 100 mL of specimen
neutralization reagent was added. Then, a 50-mL aliquot of
DNA extract was transferred to a PCR tube containing 50 mL
of amplification mixture. Amplification, hybridization, detec-
tion, and interpretation were performed according to the man-
ufacturer’s instructions.
Statistical analysis. The relationship between the bacillary
load and the rate of positive M. tuberculosis PCR test results
was assessed with Fisher’s exact test by partitioning patients
with confirmed pleural tuberculosis into 3 groups. SPSS soft-
ware, version 11.0 (SPSS), was used.
RESULTS
Subjects’ characteristics. Initially, 113 patients were enrolled
in our study, but pleural effusion specimens obtained from 2
patients (1.8%) repeatedly showed an inhibition to the ampli-
fication reaction. Therefore, the data for these 2 patients were
not included in the statistical analysis. Tuberculous pleural ef-
fusion was diagnosed in one of the patients, and parapneu-
monic effusion was diagnosed in the other.
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Table 1. Baseline characteristics of patients with tuberculous plerual effusion and patients with nontuberculous effusion and the
sensitivity and specificity of Mycobacterium tuberculosis PCR testing, acid-fast bacilli (AFB) smear, pleural effusion culture, adenosine
deaminase (ADA) activity, pleural biopsy pathology, and sputum culture.
Variable
Tuberculous
pleural
effusion group
(n p 57)
Nontuberculous
pleural
effusion group
(n p 54) Sensitivity, % Specificity, %
Female sex 17 (29.8) 12 (22.2) … …
Age, mean years (range) 43.3 (19–85) 55.9 (19–87) … …
Positive result of M. tuberculosis PCR test of pleural effusion specimen 10 1 17.5 98.1
Positive finding of AFB smear of pleural effusion specimen 2 0 3.5 …
Positive result of pleural effusion culture 14 0 24.6 …
ADA level 145 IU/L 46 3 80.7 94.4
Positive finding of pleural biopsy 32a 0b 82.1 …
Positive result of sputum culture 21 0 36.8 …
NOTE. Data is no. (%) of patients, unless indicated otherwise.
a Thirty-two of the 39 patients who underwent biopsy had a histologic finding consistent with pleural tuberculosis.
b Forty patients underwent pleural biopsy.
Of the 111 remaining patients, 57 received diagnoses of pleu-
ral tuberculosis, including confirmed and probable pleural tu-
berculosis. Patients with confirmed pleural tuberculosis (41 pa-
tients) had pleural fluid that was culture-positive for M.
tuberculosis (14 patients) and/or a histopathologic finding con-
sistent with tuberculosis on pleural biopsy (32 patients). Pa-
tients with probable pleural tuberculosis (16 patients) had spu-
tum that was culture-positive for M. tuberculosis (5 patients),
a paravertebral abscess that was culture-positive for M. tuber-
culosis (1 patient), or a positive response to antituberculosis
medication (10 patients) without other possible causes of pleu-
ral effusion. The mean age was 43.3 years for the tuberculous–
pleural-effusion group and 55.9 years for the nontuberculous–
pleural-effusion group. There were 17 women (29.8%) in the
tuberculous–pleural effusion group and 12 women (22.2%) in
the nontuberculous–pleural effusion group (table 1). The eti-
ologies of nontuberculous pleural effusion included malignancy
(in 27 [50.0%] of 54 patients with nontuberculous pleural ef-
fusion), bacterial pneumonia (in 16 patients [29.6%]), intra-
abdominal infection (in 3 patients [5.6%]), liver cirrhosis (in
2 patients [3.7%]), and sepsis (in 1 patient [1.9%]), and 5
patients (9.3%) had nontuberculous pleural effusion of an un-
determined origin.
Sensitivity and specificity of M. tuberculosis PCR testing,
AFB smear, M. tuberculosis culture, measurement of ADA
activity, and pleural biopsy pathology. Of the 57 tuberculous
pleural effusion specimens, 10 had positive M. tuberculosis PCR
test results, 2 had positive AFB smear results, 14 had positive
M. tuberculosis culture results, and 46 were determined to be
positive by measurement of ADA activity (defined as an ADA
level of 145 IU/L). Considering the combination of M. tuber-
culosis culture, pleural biopsy pathology, and clinical finding as
the reference method of diagnosing pleural tuberculosis, the
sensitivities of M. tuberculosis PCR testing of pleural effusion
specimen, AFB smearing of pleural effusion specimen, M. tu-
berculosis culture of pleural effusion specimen, and measure-
ment of ADA were 17.5%, 3.5%, 24.6%, and 80.7%, respec-
tively. Of the 57 patients with pleural tuberculosis, 39
underwent pleural biopsy, and 32 of those patients had a his-
tologic finding consistent with pleural tuberculosis. Of the 57
patients with pleural tuberculosis, 21 had a sputum culture
result that was positive for M. tuberculosis. The sensitivity of
pleural biopsy and sputum culture was 82.1% and 36.8%, re-
spectively. Of the 54 nontuberculous pleural effusion speci-
mens, 1 was PCR-positive for M. tuberculosis and 3 were ADA-
positive. The specificity of M. tuberculosis PCR testing and
measurement of ADA activity, therefore, was 98.1% and 94.4%,
respectively (table 1). We also separately evaluated the sensi-
tivity of M. tuberculosis PCR testing for patients with confirmed
and probable pleural tuberculosis. These sensitivities were al-
most equivalent to the overall sensitivity (17.1% for the group
with confirmed pleural tuberculosis and 18.8% for the group
with probable pleural tuberculosis) (table 2).
Sensitivity of M. tuberculosis PCR testing according to the
bacillary load. Patients with confirmed pleural tuberculosis
were separated into 3 groups with respect to the assumed bacillary
load in the pleural effusion. Results of M. tuberculosis PCR tests
of pleural effusion specimens were positive for 2 of 2 patients
with positive pleural effusion AFB smear results, for 4 of 12
patients with negative pleural effusion AFB smear results and
positive culture results, and for 1 of 27 patients with negative
culture results and positive pleural biopsy results. The sensitivity
of M. tuberculosis PCR testing for each group was 100.0%, 33.3%,
and 3.7%, respectively ( , by Fisher’s exact test).P ! .05
Clinical utility of M. tuberculosis PCR testing in terms of
the rapid diagnosis of pleural tuberculosis. In only 3 of the
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Table 2. Sensitivities of pleural effusion Mycobacterium tuberculosis PCR, acid-fast bacilli (AFB)
smear, M. tuberculosis culture, measurement of adenosine deaminase (ADA) activity, pleural biopsy
pathology, and sputum M. tuberculosis culture in each group of confirmed and probable tuberculous
pleural effusion.
Variable
Confirmed
tuberculous
pleural
effusion group
(n p 41)
Probable
tuberculous
pleural
effusion group
(n p 16)
Positive result of M. tuberculosis PCR test of pleural effusion specimen 7 (17.1) 3 (18.8)
Positive finding of AFB smear of pleural effusion specimen 2 (4.9) …
Positive result of pleural effusion culture 14 (34.1) …
ADA level 145 IU/L 34 (82.9) 12 (75.0)
Positive finding of pleural biopsy 32 (86.5)a 0b
Positive result of sputum culture 16 (39.0) 5 (31.3)
a Of the 37 patients who underwent biopsy, 32 had a histologic finding consistent with pleural tuberculosis.
b Of the 2 patients who underwent biopsy, none had a histologic finding consistent with pleural tuberculosis.
57 patients with pleural tuberculosis, results of the rapid di-
agnostic modalities, including pleural effusion AFB smear, spu-
tum AFB smear, pleural biopsy pathology, and measurement
of ADA activity, were all negative, except results of M. tuber-
culosis PCR testing. Pleural tuberculosis in these 3 patients was
later confirmed by pleural effusion culture and/or sputum cul-
ture. Therefore, as a rapid diagnostic laboratory method, M.
tuberculosis PCR testing of pleural effusion specimen was useful
only in 3 (5.3%) of the 57 patients with pleural tuberculosis.
DISCUSSION
With respect to tuberculous pleurisy, early in the course of a
tuberculous infection, a few organisms may gain access to the
pleura and cause a hypersensitivity response in the presence of
cell-mediated immunity [17, 18]. Commonly, this form of tu-
berculous pleurisy goes unnoticed, and it resolves spontane-
ously. In some patients, however, the tuberculous involvement
of the pleura is manifested as an acute illness with fever and
pleuritic pain. The effusion is generally small and unilateral. In
∼30% of patients, there is no radiographic evidence of involve-
ment of the lung parenchyma, despite the presence of lung
parenchymal lesions in most cases, as evidenced by findings of
lung dissections [19]. In the absence of concurrent pulmonary
tuberculosis, the diagnosis of pleural tuberculosis requires thor-
acentesis and, in most cases, even pleural biopsy [8]. For tu-
berculous pleural effusion, the number of organisms in the
pleural fluid is very small, thus, conventional methods for the
detection of M. tuberculosis are often of no use. Although the
combination of microscopic examination and culture of pleural
biopsy specimens was reported to increase the rate of diagnosis
up to 90%, it is time-consuming [20]. Thus, many physicians
request NATs, including PCR testing of pleural effusion spec-
imens, to obtain a rapid and accurate diagnosis of pleural
tuberculosis.
Several commercial and in-house NATs to detect M. tuber-
culosis in clinical specimens have been developed. These tests
amplify various targets in DNA or RNA sequences that are
genus-specific or species-specific, and this is followed by de-
tection with gel electrophoresis or hybridization. Currently,
there are 4 commercial NATs for the detection of M. tuber-
culosis: the Amplicor MTB test and its automated version, the
Cobas Amplicor MTB test; the Enhanced Amplified Mycobac-
terium Tuberculosis Direct Test (E-AMTDT) (Gen-Probe); the
BDProbe Tec ET test (Becton Dickinson); and the INNO-LiPA-
Rif TB test (Innogenetics). Of these, the E-AMTDT was ap-
proved by the US Food and Drug Administration for the direct
detection of M. tuberculosis in both smear-positive and smear-
negative respiratory specimens obtained from patients sus-
pected of having tuberculosis, and the Amplicor MTB test was
approved only for use with smear-positive respiratory speci-
mens [21–23]. With respect to in-house NATs, in previous
studies, diverse methods with different primers have been used
to detect M. tuberculosis in pleural fluid samples, with highly
variable sensitivities (11%–81%) [9–14]. Sensitivities of com-
mercial NATs have also been variable (20%–100%), because the
number of the patients with pleural tuberculosis was rather
small, and in some studies, only the culture-positive cases were
included in the pleural tuberculosis group [24–30] (table 3).
Because cases with positive culture results for M. tuberculosis
represent a relatively small portion of all the cases of pleural
tuberculosis, and because the sensitivity of M. tuberculosis PCR
testing largely depends on the bacillary load, the sensitivity for
the study group of patients with culture results positive for M.
tuberculosis does not reflect the sensitivity for all patients with
pleural tuberculosis. For these reasons, there has been no con-
sensus regarding the usefulness of M. tuberculosis PCR testing
in the diagnosis of tuberculous pleural effusion. In this study,
we used the commercially available Cobas Amplicor MTB test,
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which can minimize the intertester variabilities and maximize
the specificities because of its automated specimen processing
and detection. And the combination of M. tuberculosis culture,
pleural pathological analysis, and clinical diagnosis was em-
ployed as the reference method for diagnosing pleural
tuberculosis.
In Korea, tuberculosis is still a major infectious disease. We
examined the clinical utility of M. tuberculosis PCR testing in
the diagnosis of pleural tuberculosis with respect to its sensi-
tivity, specificity, and usefulness in terms of a rapid diagnostic
method. Our study demonstrated that M. tuberculosis PCR test-
ing of pleural effusion specimens has a lower sensitivity (17.5%)
than do mycobacterial culture of pleural effusion specimens
(24.6%) and pathologic examination of pleural biopsy speci-
mens (82.1%). The sensitivity of M. tuberculosis PCR testing
of pleural effusion specimens for each group of patients who
had smear-positive, smear-negative and culture-positive, and
culture-negative and pleural biopsy pathology–positive results
was 100.0%, 33.3%, and 3.7%, respectively. These results in-
dicate that the sensitivity of M. tuberculosis PCR testing is largely
dependent on the bacillary load in the specimens, which is in
accordance with the previous studies [30–33]. Therefore, for
the specimens such as pleural effusion specimens, in which the
bacillary load is very low, the clinical utility of M. tuberculosis
PCR testing seems highly limited. Among the 57 patients with
pleural tuberculosis, only 3 (5.3%) had a positive result of M.
tuberculosis PCR testing and a negative smear result, a negative
finding of pleural biopsy, and a low level of ADA activity.In
terms of the rapid detection of M. tuberculosis in pleural ef-
fusion, therefore, M. tuberculosis PCR testing does not seem to
be very helpful. Of the 11 patients with a positive result of M.
tuberculosis PCR tests of pleural effusion specimens, 1 received
a diagnosis of malignant pleural effusion due to metastatic
breast cancer, which was confirmed by cytologic examination
of a pleural effusion specimen. This patient was an 84-year-old
woman who did not have any clinical or radiological evidence
of previous tuberculosis. This false-positive result might have
originated from cross-contamination during specimen pro-
cessing, from cross-reaction with nonmycobacterial DNA, or
from latent infection with tuberculosis [34–37]. Johansen et al.
[37] suggested that the lung tissue of persons residing in an
area where M. tuberculosis is endemic could be colonized with
a small amount of M. tuberculosis without active infection that
was detectable by PCR testing. Because the prevalence of tu-
berculosis is still high in Korea, this might explain the false-
positive M. tuberculosis PCR result in our study. Therefore, the
positive M. tuberculosis PCR result should be carefully inter-
preted in conjunction with results of mycobacterial culture,
findings of histopathologic examination of pleural biopsy spec-
imens, and clinical findings to reach the diagnosis of tuber-
culous pleural effusion.
The sensitivity of NAT depends not only on the number of
mycobacteria but also on their homogenous distribution in the
specimen, the presence of the amplification inhibitor in the
sample, and the type of the primers that are used [38]. When
applying the M. tuberculosis PCR test to paucibacillary speci-
mens, therefore, all of these aspects should also be considered.
In conclusion, although M. tuberculosis PCR testing provides
a rapid result and has a potential role in confirming tuberculous
pleuritis, it has limitations in itself. Our results suggest that M.
tuberculosis PCR testing of pleural effusion specimens with the
Cobas Amplicor MTB test has a low sensitivity and thus does
not seem to be useful in excluding the disease. Therefore, it
cannot replace the conventional diagnostic methods, including
culture techniques and histopathologic examinations. Further-
more, the results of M. tuberculosis PCR tests need to be in-
terpreted in conjunction with those of conventional methods
and clinical findings to reach the final diagnosis of pleural
tuberculosis.
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